94,812 longitudinal RT-qPCR measurements from anterior nares and oropharyngeal swabs. Compared the SARS-CoV-2 viral kinetics of first vs. second infections, adjusting for viral variant, vaccination status, and age.
#immunology101 would strongly suggest that relative to first infections, second infections have reduced pathogen burden, faster clearance, especially in those who received a vaccine dose in addition. But some have contributed near magical properties to SARS-CoV-2.Wee
Not unexpectedly: the secondary SARS-CoV-2 infection shows less viral burden, and is reduced in time in the upper respiratory tract.
If a person was also vaccinated between first and second infection; the clearance was even quicker:
If you are genetically predisposed to clear a virus more quickly, you are likely to do so as well a second time. Also that makes sense.
What we see is what is expected; our immune system works as it should: providing protection against SC2, generating and responding with a quicker memory response.
The quicker resolution will mean shorter transmission period, less likely to get ill, less duration of symptoms.
What would be nice to see is also dissemination data: In primary infection the virus is more likely to escape immune control and affect more tissues, this should be much curtailed upon subsequent infections.
A large part of the quick clearance correlates strongly with activated T cells. Those not in the blood but already at the site of infection will even enhance this response.
Bivalent boosters protected better the elderly:
Among elderly aged 65–120 years, bivalent vaccination reduced the risk of hospitalisation and death due to COVID-19. This is particular true in the first weeks to months, but waning will happen; elderly make less powerful responses.
Among the chronically ill aged 18–64 years bivalent vaccination did not reduce the risk of severe COVID-19 outcomes. i.e. If you are chronically ill with a weak immune system, vaccination (=your immune system) will in some not make a difference.
That other viruses do it, does not make it less bad for those affected. However, do keep the context in mind. SARS-CoV-2 is a harmful virus, especially prior to immunity and for immunocompromised.
Infection can trigger antibody polyreactivity and autoimmunity which are generally deleterious. But, naturally arising chemokine antibodies may modulate the inflammatory response and thus bear therapeutic potential.
n=71, 8 March 2020 and 22 November 2020, no vaccine.
No correlation between the amounts of chemokines and the amounts of corresponding autoantibodies in the acute phase or at month 7 post-infection.
Outpatient Treatment of COVID-19 and the Development of Long COVID Over 10 Months: A Multi-Center, Quadruple-Blind, Parallel Group Randomized Phase 3 Trial
Inclusion criteria included: age 30 to 85 years with overweight or obesity (!), symptoms <7 days, enrolled within <=3 days of documented SARS-CoV-2 infection.
Long COVID diagnosis from a medical provider was a pre-specified secondary outcome assessed by monthly surveys through 300 days after randomization and confirmed in medical records.
Excess mortality for 11 months of 2022 is 11%, expectation is that excess mortality for the full year 2022 will be 12% i.e. nearly 20,000 more deaths in 2022 than if the pandemic had not happened.
Just over half of the expected excess mortality for 2022 is due to deaths from COVID-19 (+10,300 deaths), with another +2,900 where COVID-19 was a contributing factor, and the remaining excess of +6,600 with no mention of COVID-19 on the death certificate.
While most of the excess deaths are in older age groups (i.e. 65+ years), excess mortality is a significant percentage in all age groups in 2022.
The study has 30 healthy controls and 166 COVID-19 patients, recruited 8/2020-8/2021; no vaccines.
Patients with COVID-19 were divided into 2 groups according to the sample collection period: 0–15 days after diagnosis (n = 121) and 45–60 days after diagnosis (n=45).
Limitations:
-Different stages of the disease
-The acute and convalescent samples were not taken from the same patients.
-Those hospitalized used different
medications, which can affect their immunological and inflammatory profile.
-the patient groups had several comorbidities